The use of dexmedetomidine in anesthesia and intensive care: A review

Current Pharmaceutical Design

Volumn 18, Issue 38, 2012, Pages 6257-6265

  Farag, Ehab ^a   Argalious, Maged ^a   Abd Elsayed, Alaa ^b   Ebrahim, Zeyd ^a   Doyle, D John ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Anesthesia; Dexmedetomidine; Surgery

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ATIPAMEZOLE; BUPIVACAINE; CLONIDINE; DEXMEDETOMIDINE; FENTANYL; HALOTHANE; ISOFLURANE; MIDAZOLAM; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MORPHINE; NORADRENALIN; OXYCODONE; PENTOBARBITAL; PLACEBO; SYNAPSIN I; TRAMADOL;

ANESTHESIA; ANTIINFLAMMATORY ACTIVITY; APNEA; BRADYCARDIA; BRAIN BLOOD FLOW; CARDIOTOXICITY; CAROTID ENDARTERECTOMY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG USE; ELECTROENCEPHALOGRAM; GASTROINTESTINAL ENDOSCOPY; HEART INDEX; HEART RATE; HUMAN; HYPERTENSION; HYPOTENSION; INTENSIVE CARE; NEUROPROTECTION; NONHUMAN; OXYGEN SATURATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINUS ARREST; TACHYCARDIA;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ANESTHESIA; ANIMALS; BRADYCARDIA; CEREBROVASCULAR CIRCULATION; CRITICAL ILLNESS; DEXMEDETOMIDINE; DRUG ADMINISTRATION ROUTES; DRUG INTERACTIONS; ENDOSCOPY, GASTROINTESTINAL; HUMANS; HYPNOTICS AND SEDATIVES; HYPOTENSION; INTENSIVE CARE; NEUROPROTECTIVE AGENTS;

EID: 84873942311     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212803832272     Document Type: Review

References (118)

1. Su F, Hammer GB. Dexmedetomidine: pediatric pharmacology, clinical uses and safety. Expert Opin Drug Saf 2011; 10: 55-66.
2. Maze M, Scarfini C, Cavaliere F. New agents for sedation in the intensive care unit. Crit Care Clin 2001; 17: 881-97.
3. Petroz GC, Sikich N, James N, et al. A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. Anesthesiology 2006; 105: 1074-5.
4. Potts AL, Warman GR, Anderson BJ. Dexmedetomidine disposition in children: a population analysis. Paediatr Anaesth 2008; 18: 722-30.
5. Venn RM, Bradshaw CJ, Spencer R et al. PreliminaryUK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia 1999; 54: 1136-42.
6. Vilo S, Rautiainen P, Aantaa R et al. Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. Br J Anaesth 2008; 100: 697-700.
7. Iirola T, Ihmsen H, Laitio R, et al. Population pharmacokinetics of dexmedetomidine during long-term sedation in intensive care patients. Br J Anaesth 2012; Jan 25, doi: 10.1093/bja/aer441].
8. Ala-Kokko TI, Pienimäki P, Lampela E, Hollmén AI, Pelkonen O, Vähäkangas K. Transfer of clonidine and dexmedetomidine across the isolated perfused human placenta. Acta Anaesthesiol Scand 1997; 41: 313-9.
9. De Wolf AM, Fragen RJ, Avram MJ, Fitzgerald PC, Rahimi-Danesh F. The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. Anesth Analg 2001; 93: 1205-9.
10. Prommer E. Dexmedetomidine: Does it have potential in palliative medicine? Am J Hosp Palliat Care 2011; 28: 276-83.
11. Talke P, Lobo E, Brown R. Systemically administered [alpha]2-agonist-induced peripheral vasoconstriction in humans. Anesthesiology 2003; 99: 65-70.
12. Figueroa XF, Poblete MI, Boric MP, Mendizábal VE, Adler-Graschinsky E, Huidobro-Toro JP. Clonidine-induced nitric oxidedependent vasorelaxation mediated by endothelial alpha(2)-adrenoceptor activation. Br J Pharmacol 2001; 134: 957-68.
13. Link RE, Desai K, Hein L, et al. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science 1996; 273: 803-5.
14. Indolfi C, Piscione F, Villari B, et al. Role of alpha 2-adrenoceptors in normal and atherosclerotic human coronary circulation. Circulation 1992; 86: 1116-24.
15. Baumgart D, Haude M, Gorge G, et al. Augmented alphaadrenergic constriction of atherosclerotic human coronary arteries. Circulation 1999; 99: 2090-7.
16. Feldman J, Fellmann L, Bousquet P. The central hypotensive effect induced by a2-adrenergic receptor stimulation is dependent on endothelial nitric oxide synthase. J Hypertens 2008; 26: 1033-1036.
17. Snapir A, Posti J, Kentala E. Effects of low and high plasma concentrations of dexmedetomidine on myocardial perfusion and cardiac function in healthy male subjects. Anesthesiology 2006; 105: 902-10.
18. Talke P, Richardson CA, Scheinin M, Fisher DM. Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. Anesth Analg 1997; 95: 1136-42.
19. Talke P, Li J, Jain U, et al. Effects of perioperative dexmedetomidine infusion in patients undergoing vascular surgery. The Study of Perioperative Ischemia Research Group. Anesthesiology 1995; 82: 620-33.
20. Oliver MF, Goldman L, Julian DG, Holme I. Effect of mivazerol on perioperative cardiac complications during non-cardiac surgery in patients with coronary heart disease: the European Mivazerol Trial (EMIT). Anesthesiology 1999; 91: 951-61.
21. Biccard BM, Goga S, de Beurs J. Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials. Anaesthesia 2008; 63: 4-14.
22. McCutcheon CA, Orme RM, Scott DA, et al. A comparison of dexmedetomidine versus conventional therapy for sedation and hemodynamic control during carotid endarterectomy performed under regional anesthesia. Anesth Analg 2006; 102: 668-75.
23. Chrysostomou C, Beerman L, Shiderly D, et al. Dexmedetomidine: a novel drug for the treatment of atrial and junctional tachyarrhythmias during the perioperative period for congenital cardiac surgery: a preliminary study. Anesth Analg 2008; 107: 1514-22.
24. Menon DV, Wang Z, Fadel PJ. Central sympatholysis as a novel countermeasure for cocaine-induced sympathetic activation and vasoconstriction in humans. J Am Coll Cardiol 2007; 50: 626-33.
25. 2-adrenoceptor agonist dexmedetomidine. Hypertension 2008; 51: 406-411.
26. Wong J, Steil GA, Curtis M, et al. Cardiovascular effects of dexmedetomidine sedation in children. Anesth Analg 2012; 114: 193-9.
27. Engelhard K. Werner C, Kaspar S, et al. Effect of the [alpha]2-agonist dexmedetomidine on cerebral neurotransmitter concentrations during cerebral ischemia in rats. Anesthesiology 2002; 96: 450-7.
28. Ma D, Rajakumaraswamy N, Maze M. alpha2-adrenoceptor agonists: shedding light on neuroprotection? Br Med Bull 2005; 71: 77-92.
29. Huang R, Chen Y, Yu AC, Hertz L. Dexmedetomidine-induced stimulation of glutamine oxidation in astrocytes: a possible mechanism for its neuroprotective activity. J Cereb Blood Flow Metab 2000; 20: 895-8.
30. Chiu KM, Lin TY, Lu CW, Wang SJ. Inhibitory effect of glutamate release from rat cerebrocortical nerve terminals by rr2 adrenoceptor agonist dexmedetomidine. Eur J Pharmacol 2011; 670: 137-47.
31. Engelhard K, Werner C, Eberspächer E, et al. The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg 2003; 96: 524-31.
32. Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol 2003; 48 Suppl 1: S47-51.
33. Mantz J, Josserand J, Hamada S. Dexmedetomidine: new insights. Eur J Anaesthesiol 2011; 28: 3-6.
34. Ma D, Hossain M. Rajakumaraswamy N, et al. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol 2004; 502: 87-97.
35. Sanders RD, Xu J, Shu Y, et al. Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. Anesthesiology 2009; 110: 1077-85.
36. Karlsson BR, Forsman M, Roald OK, Heier MS, Steen PA. Effect of dexmedetomidine, a selective and potent alpha 2-agonist, on cerebral blood flow and oxygen consumption during halothane anesthesia in dogs. Anesth Analg 1990; 71: 125-9.
37. Asano Y, Koehler RC, Kawaguchi T, McPherson RW. Pial arteriolar constriction to alpha 2-adrenergic agonist dexmedetomidine in the rat. Am J Physiol 1997; 272: H2547-56.
38. McPherson RW, Koehler RC, Kirsch JR, Traystman RJ. Intraventricular dexmedetomidine decreases cerebral blood flow during normoxia and hypoxia in dogs. Anesth Analg 1997; 139-47.
39. Ogawa Y, Iwasaki K, Aoki K, Kojima W, Kato J, Ogawa S. Dexmedetomidine weakens dynamic cerebral autoregulation as assessed by transfer function analysis and the thigh cuff method. Anesthesiology 2008; 109: 642-50.
40. Kadoi Y, Saito S, Kawauchi C, Hinohara H, Kunimoto F. Comparative effects of propofol vs dexmedetomidine on cerebrovascular carbon dioxide reactivity in patients with septic shock. Br J Anaesth 2008; 100: 224-9.
41. Iida H, Iida M, Ohata H, Dohi S. Effects of dexmedetomidine on cerebral circulation and systemic hemodynamics after cardiopulmonary resuscitation in dogs. J Anesth 2006; 20: 202-7.
42. Chi OZ, Hunter C, Liu X, Weiss HR. The effects of dexmedetomidine on regional cerebral blood flow and oxygen consumption during severe hemorragic hypotension in rats. Anesth Analg 2011; 113: 349-55.
43. Drummond JC, DaoAV, Roth DM, et al. Effect of dexmedetomidine on cerebral blood flow velocity, cerebral metabolic rate, and carbon dioxide response in normal humans. Anesthesiology 2008; 108: 225-32.
44. Fale A, Kirsch JR, McPherson RW. Alpha 2-adrenergic agonist effects on normocapnic and hypercapnic cerebral blood flow in the dog are anesthetic dependent. Anesth Analg 1994; 79: 892-8.
45. Farag E. Dexmedetomidine in the neurointensive care unit. Discov Med 2010; 9: 42-5.
46. Nelson LE, Lu J, Guo T, Saper CB, Franks NP, Maze M. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology 2003; 98: 428-36.
47. Maze M, Bonnet F. Analgesics. Receptor ligands-adrenergic receptor agonists. In: Evers AS, Maze M, eds. Anesthetic Pharmacology: Physiologic Principles and Clinical Practice. Philadelphia: Churchill Livingstone, 2004; 473-89.
48. Coull JT, Jones ME, Egan TD, Frith CD, Maze M. Attentional effects of noradrenaline vary with arousal level: selective activation of thalamic pulvinar in humans. Neuroimage 2004; 22: 315-22.
49. Pandharipande PP, Bun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA 2007; 298: 2644-53.
50. Ruokonen E, Parviainen I, Jakob SM. Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation. Intensive Care Med 2009; 35: 282-90.
51. Shukry M. Clyde MC, Kalarickal PL, Ramadhyani U. Does dexmedetomidine prevent emergence delirium in children after sevoflurane-based general anesthesia? Paediatr Anaesth 2005; 15: 1098-104.
52. Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009; 301: 489-99.
53. Reade MC, O'Sullivan K, Bates S, Goldsmith D, Ainslie WR, Bellomo R. Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Crit Care 2009; 13: R75.
54. Shehabi Y, Nakae H, Hammond N, Bass F, Nicholson L. Chen J. The effect of dexmedetomidine on agitation during weaning of mechanical ventilation in critically ill patients. Anaesth Intensive Care 2010; 38: 82-90.
55. Shehabi Y, Grant P, Wolfenden H, et al. Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled trial (DEXmedetomidine COmpared to Morphine-DEXCOM Study). Anesthesiology 2009; 111: 1075-84.
56. Dasta JF, Kane-Gill SL, Pencina M, et al. A cost-minimization analysis of dexmedetomidine compared with midazolam for longterm sedation in the intensive care unit. Crit Care Med 2010; 38: 497-503.
57. Hofer S, Steppan J, Wagner T, et al. Central sympatholytics prolong survival in experimental sepsis. Crit Care 2009; 13: R11.
58. Can M, Gul S, Bektas S, Hanci V, Acikgoz S. Effects of dexmedetomidine or methylprednisolone on inflammatory responses in spinal cord injury. Acta Anaesthesiol Scand 2009; 53: 1068-72.
59. Kumagai M, Horiguchi T, Nishikawa T, Masaki Y, Tobe Y. Intravenous dexmedetomidine decreases lung permeability induced by intracranial hypertension in rats. Anesth Analg 2008; 107: 643-7.
60. Smyth DD, Umemura S, Pettinger WA. Alpha 2-adrenoceptor antagonism of vasopressin-induced changes in sodium excretion. Am J Physiol 1985; 248 (6 Pt 2): F767-72.
61. Pettinger WA. Renal alpha 2-adrenergic receptors and hypertension. Hypertension 1987; 9: 3-6.
62. Chen M, Lee J, Huang BS, Grekin RJ, Malvin RL. Clonidine and morphine increase atrial natriuretic peptide secretion in anesthetized rats. Proc Soc Exp Biol Med 1989; 191: 299-303.
63. Billings FT 4th, Chen SW, Kim M, et al. alpha2-Adrenergic agonists protect against radiocontrast-induced nephropathy in mice. Am J Physiol Renal Physiol 2008; 295: F741-8.
64. Joris J, Banache M, Bonnet F, Sessler DI, Lamy M. Clonidine and ketanserin both are effective treatment for postanesthetic shivering. Anesthesiology 1993; 79: 532-9.
65. Memi D, Dökmeci D, Karamanliolu B, Turan A, Türe M. A comparison of the effect on gastric emptying of propofol or dexmedetomidine in critically ill patients: preliminary study. Eur J Anaesthesiol 2006; 23: 700-4.
66. Segal IS, Vickery RG, Walton JK, Doze VA, Maze M. Dexmedetomidine diminishes halothane anesthetic requirements in rats through a postsynaptic alpha 2 adrenergic receptor. Anesthesiology 1988; 69: 818-23.
67. Tobias JD, Goble TJ, Bates G, Anderson JT, Hoernschemeyer DG. Effects of dexmedetomidine on intraoperative motor and somatosensory evoked potential monitoring during spinal surgery in adolescents. Paediatr Anaesth 2008; 18: 1082-8.
68. Bala E, Sessler DI, Nair DR, McLain R, Dalton JE, Farag E. Motor and somatosensory evoked potentials are well maintained in patients given dexmedetomidine during spine surgery. Anesthesiology 2008; 109: 417-25.
69. Souter MJ, Rozet I, Ojemann JG, et al. Dexmedetomidine sedation during awake craniotomy for seizure resection: effects on electrocorticography. J Neurosurg Anesthesiol 2007; 19: 38-44.
70. Ard J, Doyle W, Bekker A. Awake craniotomy with dexmedetomidine in pediatric patients. J Neurosurg Anesthesiol 2003; 15: 263-6.
71. Ard JL Jr, Bekker AY, Doyle WK. Dexmedetomidine in awake craniotomy: a technical note. Surg Neurol 2005; 63: 114-6; discussion 116-7.
72. Bekker AY, Kaufman B, Samir H, Doyle W. The use of dexmedetomidine infusion for awake craniotomy. Anesth Analg 2001; 92: 1251-3.
73. Mack PF, Perrine K, Kobylarz E, Schwartz TH, Lien CA. Dexmedetomidine and neurocognitive testing in awake craniotomy. J Neurosurg Anesthesiol 2004; 16: 20-5.
74. Takenaka M, Iida H, Iida M, Dohi S. Intrathecal dexmedetomidine attenuates hypercapnic but not hypoxic cerebral vasodilation in anesthetized rabbits. Anesthesiology 2000; 92: 1376-84.
75. Ohata H, Iida H, Dohi S, Watanabe Y. Intravenous dexmedetomidine inhibits cerebrovascular dilation induced by isoflurane and sevoflurane in dogs. Anesth Analg 1999; 89: 370-7.
76. Khatib R, Ebrahim Z, Rezai A, et al. Perioperative events during deep brain stimulation: the experience at Cleveland Clinic. J Neurosurg Anesthesiol 2008; 20: 36-40.
77. Rozet I, Muangman S, Vavilala MS, et al. Clinical experience with dexmedetomidine for implantation of deep brain stimulators in Parkinson's disease. Anesth Analg 2006; 103: 1224-8.
78. th ed. London: Rapid Science, 1997; 1-14.
79. Demiraran Y, Korkut E, Tamer A, et al. The comparison of dexmedetomidine and midazolam used for sedation of patients during upper endoscopy: A prospective, randomized study. Can J Gastroenterol 2007; 21: 25-9.
80. Jalowiecki P, Rudner R, Gonciarz M, Kawecki P, Petelenz M, Dziurdzik P. Sole use of dexmedetomidine has limited utility for conscious sedation during outpatient colonoscopy. Anesthesiology 2005; 103: 269-73.
81. Bergese SD, Candiotti KA, Bokesch PM, et al. A Phase IIIb, randomized, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of dexmedetomidine for sedation during awake fiberoptic intubation. Am J Ther 2010; 17: 586-95.
82. Ryu JH, Lee SW, Lee JH, et al. Randomized double-blind study of remifentanil and dexmedetomidine for flexible bronchoscopy. Br J Anaesth 2011; December 15.
83. Bergese SD, Patrick BS, Mc Sweeney TD, et al A comparative study of dexmedetomidine with midazolam and midazolam alone for sedation during elective awake fiberoptic intubation. J Clin Anesth 2010; 22: 35-40.
84. Avitsian R, Lin J, Lotto M, Ebrahim Z. Dexmedetomidine and awake fiberoptic intubation for possible cervical spine myelopathy: a clinical series. J Neurosurg Anesthesiol. 2005; 17(2): 97-9.
85. Abdelmalak B, Makary L, Hoban J, Doyle DJ. Dexmedetomidine as sole sedative for awake intubation in management of the critical airway. J Clin Anesth. 2007 Aug; 19(5): 370-3.
86. Abdelmalak B, Marcanthony N, Abdelmalak J, Machuzak MS, Gildea TR, Doyle DJ. Dexmedetomidine for anesthetic management of anterior mediastinal mass. J Anesth 2010; 24(4): 607-10.
87. Abdelmalak B, Gutenberg L, Lorenz RR, Smith M, Farag E, Doyle DJ. Dexmedetomidine supplemented with local anesthesia for awake laryngoplasty. J Clin Anesth. 2009 Sep; 21(6): 442-3.
88. Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: a review of clinical applications. Curr Opin Anaesthesiol 2008; 21: 457-61.
89. Fragen RJ, Fitzgerald PC. Effect of dexmedetomidine on the minimum alveolar concentration (MAC) of sevoflurane in adults age 55 to 70 years. J Clin Anesth 1999; 11: 466-70.
90. Kagawa K, Mammoto T, Hayashi Y, Kamibayashi T, Mashimo T, Yoshiya I. The effect of imidazoline receptors and alpha2-adrenoceptors on the anesthetic requirement (MAC) for halothane in rats. Anesthesiology 1997; 87: 963-7.
91. Khan ZP, Munday IT, Jones RM, Thornton C, Mant TG, Amin D. Effects of dexmedetomidine on isoflurane requirements in healthy volunteers. 1: Pharmacodynamic and pharmacokinetic interactions. Br J Anaesth 1999; 83: 372-80.
92. Dutta S, Karol MD, Cohen T, Jones RM, Mant T. Effect of dexmedetomidine on propofol requirements in healthy subjects. J Pharm Sci 2001; 90: 172-81.
93. Talke PO, Caldwell JE, Richardson CA, Kirkegaard-Nielson H, Stafford M. The effects of dexmedetomidine on neuromuscular blockade in human volunteers. Anesth Analg 1999; 88: 633-9.
94. Narimatsu E, Niiya T, Kawamata M, Namiki A. Lack in effects of therapeutic concentrations of dexmedetomidine and clonidine on the neuromuscular blocking action of rocuronium in isolated rat diaphragms. Anesth Analg 2007; 104: 1116-20.
95. Iida H, Ohata H, Iida M, Watanabe Y, Dohi S. Direct effects of alpha-1 and alpha-2 adrenergic agonists on spinal and cerebral pial vessels in dogs. Anesthesiology 1999; 91: 479-85.
96. Konakci S, Adanir T, Yilmaz G, Rezanko T The efficacy and neurotocixity of dexmedetomidine administered via the epidural route. Eur J Anaesthesiol 2007; 25: 1-7.
97. Sabbe MB, Penning JP, Ozaki GT, Yaksh TL. Spinal and systemic action of the alpha 2 receptor agonist dexmedetomidine in dogs. Antinociception and carbon dioxide response. Anesthesiology 1994; 80: 1057-72.
98. Lehtimäki J, Leino T, Koivisto A, et al. In vitro and in vivo profiling of fadolmidine, a novel potent alpha(2)-adrenoceptor agonist with local mode of action. Eur J Pharmacol 2008; 599: 65-71.
99. Pertovaara A. Antinociceptive properties of fadolmidine (MPV-2426), a novel alpha2-adrenoceptor agonist. CNS Drug Rev 2004; 10: 117-26.
100. Horvath G, Kekesi G, Dobos I, Klimscha W, Benedek G. Longterm changes in the antinociceptive potency of morphine or dexmedetomidine after a single treatment. Anesth Analg 2005; 101: 812-8.
101. Brummett CM, Padda AK, Amodeo FS, et al. Perineural dexmedetomidine added to ropivacaine causes a dose-dependent increase in the duration of thermal antinociception in sciatic nerve block in rat. Anesthesiology 2009; 111; 1111-9
102. Memi D, Turan A, Karamanliolu, Pamukçu Z, Kurt I. Adding dexmedetomidine to lidocaine for intravenous regional anesthesia. Anesth Analg 2004; 98: 835-40.
103. Esmaoglu A, Mizrak A, Akin A, Turk Y, Boyaci A. Addition of dexmedetomidine to lidocaine for intravenous regional anaesthesia. Eur J Anaesthesiol 2005; 22: 447-51.
104. Hong JY, Kim WO, Yoon Y, Choi Y, Kim SH, Kil HK. Effects of intravenous dexmedetomidine on low-dose bupivacaine spinal anesthesia in elderly patients. Acta Anaesthesiol Scand 2012, Jan 4.
105. Arain SR, Ruehlow RM, Uhrich TD, Ebert TJ. The efficacy of dexmedetomidine versus morphine for postoperative analgesia after major inpatient surgery. Anesth Analg 2004; 96: 153-8.
106. Khaled R, AI-Zaben, Ibraheem Y, et al. Intraoperative administration of dexmedetomidine reduces the analgesic requirements for childern undergoing hypospadius surgery. Eur J Anesthesiol 2010; 27: 247-52.
107. Ramsay MA. Bariatric surgery: the role of dexmedetomidine. Semin Anesth Periop Med Pain 2006; 25: 51-6.
108. Feld JM, Hoffman WE, Stechert MM, Hoffman IW, Ananda RC. Fentanyl or dexmedetomidine combined with desflurane for bariatric surgery. J Clin Anesth 2006; 18: 24-8.
109. Anttila M, Penttilä J, Helminen A, Vuorilehto L. Scheinin H. Bioavailability of dexmedetomidine after extravascular doses in healthy subjects. Br J Clin Pharmacol 2003; 56: 691-3.
110. Yuen VM, Hui TW, Irwin MG, Yuen MK. A comparison of intranasal dexmedetomidine and oral midazolam for premedication in pediatric anesthesia: a double-blinded randomized controlled trial. Anesth Analg 2008; 106: 1715-21.
111. Koroglu A, Demirbilek S, Teksan H, Sagir O, But AK, Ersoy MO. Sedative, haemodynamic and respiratory effects of dexmedetomidine in children undergoing magnetic resonance imaging examination: preliminary results. Br J Anaesth 2005; 94: 821-4.
112. Koroglu A, Teksan H, Sagir O, Yucel A, Toprak HI, Ersoy OM. A comparison of the sedative, hemodynamic, and respiratory effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging. Anesth Analg 2006; 103: 63-7.
113. Shukry M, Ramadhyani U. Dexmedetomidine as the primary sedative agent for brain radiation therapy in a 21-month-old child. Paediatr Anaesth 2005; 15: 241-2.
114. Hammer GB, Drover DR, Cao H, et al. The effects of dexmedetomidine on cardiac electrophysiology in children. Anesth Analg 2008; 106: 79-83.
115. Shukry M, Guruli ZV, Ramadhyani U. Suspected malignant hyperthermia in a child with laminin alpha2 (merosin) deficiency in the absence of a triggering agent. Paediatr Anaesth 2006; 16: 462-5.
116. Hosokawa K, Shime N, Kato Y, et al. Dexmedetomidine sedation in children after cardiac surgery. Pediatr Crit Care Med 2010; 11: 39-43.
117. Phan J, Nahata MC. Clinical uses of dexmedetomidine in pediatric patients. Paediatr Drugs 2008; 10: 49-69.
118. Tobias JD. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology. Pediatr Crit Care Med 2007; 8: 115-31.